Lipidoses: Clinical Trials

76 trials for Lipidoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

76 completed. 76 Phase 2, 24 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 276Completed 76
Phase 124Completed 24
Phase 36Completed 6

Follow Lipidoses: new trials by email Literature Review of Lipidoses trials Research Report on Lipidoses

Trials (filtered) newest first · largest first

All 76 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
AZ-3102 (Dose 1), Placebo, AZ-3102 (Dose 2) - GM2 Gangliosidosis, Niemann-Pick Disease, Type C
Phase 2CompletedAzafaros B.V.132023-04-242026-05-14
ADX-629 Therapy for Sjogren-Larsson Syndrome
ADX-629 - Sjogren-Larsson Syndrome
Phase 1 / Phase 2CompletedUniversity of Nebraska82023-01-022026-05-05
A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.
Enzyme replacement therapy for Gaucher disease in combination with altus care application - Gaucher Disease Type 1
Phase 2CompletedHadassah Medical Organization52022-04-012023-09-22
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease
Miglustat 100 milligrams (mg) Oral Capsule - Batten Disease
Phase 1 / Phase 2CompletedBeyond Batten Disease Foundation62022-03-102025-09-09
A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
Olipudase alfa - Acid Sphingomyelinase Deficiency
Phase 2CompletedSanofi32021-11-182026-04-13
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
IB1001 - Niemann-Pick Disease, Type C
Phase 2CompletedIntraBio Inc332019-09-042023-11-28
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
ST-920 - Fabry Disease
Phase 1 / Phase 2CompletedSangamo Therapeutics362019-07-232026-10-27
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
IB1001 - GM2 Gangliosidosis, Tay-Sachs Disease
Phase 2CompletedIntraBio Inc302019-06-072024-03-12
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
SHP611 - Metachromatic Leukodystrophy (MLD)
Phase 2CompletedShire362019-05-132026-07-10
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy
Ambroxol - Gaucher Disease, Type 1
Phase 2CompletedShaare Zedek Medical Center402019-03-012023-02-14
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
VTS-270 - Niemann-Pick Disease, Type C
Phase 1 / Phase 2CompletedWashington University School of Medicine42019-02-222026-01-05
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
MGTA-456 - Inherited Metabolic Disorders (IMD)
Phase 2CompletedMagenta Therapeutics, Inc.82018-02-092021-11-03
A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)
OTL-200 - Lysosomal Storage Disease, Metachromatic Leukodystrophy
Phase 2CompletedOrchard Therapeutics102018-01-252026-03-16
Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients
Hydroxypropyl-beta-cyclodextrin - Niemann-Pick Disease, Type C1
Phase 1 / Phase 2CompletedCyclo Therapeutics, Inc.122017-03-202021-08-10
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
arimoclomol, Placebo - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedZevraDenmark502016-06-142024-11-29
Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease
AT-GTX-501 - Variant Late-Infantile Neuronal Ceroid Lipofuscinosis
Phase 1 / Phase 2CompletedEmily de los Reyes132016-05-012025-10-24
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1), Intracerebroventricular access device - Jansky-Bielschowsky Disease, Batten Disease
Phase 2CompletedBioMarin Pharmaceutical142016-01-222025-02-17
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
placebo (saline), Olipudase alfa - Sphingomyelin Lipidosis
Phase 2 / Phase 3CompletedGenzyme, a Sanofi Company362015-12-182024-11-07
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedMandos LLC562015-10-012023-02-22
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
N-acetylcysteine - Gaucher Disease Type 1
Phase 2CompletedUniversity of Minnesota332015-09-012026-02-18

Showing 20 of 76. Sign in to see all of them.

Narrower conditions

Fabry Disease (19)  ·  Gaucher Disease (15)  ·  Leukodystrophy, Metachromatic (12)  ·  Niemann-Pick Disease, Type C (9)  ·  Lysosomal Storage Diseases (8)  ·  Neuronal Ceroid-Lipofuscinoses (8)  ·  Wolman Disease (6)  ·  Sandhoff Disease (5)  ·  Tay-Sachs Disease (5)  ·  Cholesterol Ester Storage Disease (4)  ·  Gangliosidoses, GM2 (4)  ·  Leukodystrophy, Globoid Cell (4)  ·  Niemann-Pick Disease, Type A (4)  ·  Niemann-Pick Diseases (4)  ·  Stroke (4)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (76)  ·  Nutritional and Metabolic Diseases (76)  ·  Lipid Metabolism Disorders (75)  ·  Lipid Metabolism, Inborn Errors (75)  ·  Metabolic Diseases (75)  ·  Genetic Diseases, Inborn (74)  ·  Metabolism, Inborn Errors (73)  ·  Nervous System Diseases (71)  ·  Brain Diseases (64)  ·  Central Nervous System Diseases (64)  ·  Brain Diseases, Metabolic (63)  ·  Brain Diseases, Metabolic, Inborn (63)  ·  Lysosomal Storage Diseases, Nervous System (63)  ·  Sphingolipidoses (61)

Interventions

agalsidase alfa (7)  ·  larazotide acetate (5)  ·  migalastat (5)  ·  Sebelipase alfa (4)  ·  olipudase alfa (4)  ·  2-Hydroxypropyl-beta-cyclodextrin (3)  ·  AT2101 (3)  ·  Glucosylceramidase (3)  ·  agalsidase beta (3)  ·  cerliponase alfa (3)  ·  miglustat (3)  ·  Acetylcysteine (2)  ·  Alemtuzumab (2)  ·  Busulfan (2)  ·  Cyclophosphamide (2)

Sponsors

Shire (10)  ·  Amicus Therapeutics (8)  ·  Genzyme, a Sanofi Company (8)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (5)  ·  Alexion Pharmaceuticals, Inc. (4)  ·  BioMarin Pharmaceutical (3)  ·  Masonic Cancer Center, University of Minnesota (3)  ·  Protalix (3)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)  ·  IntraBio Inc (2)  ·  Orchard Therapeutics (2)  ·  The Hospital for Sick Children (2)  ·  Actelion (1)  ·  Aldeyra Therapeutics, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

United States (54)  ·  United Kingdom (28)  ·  France (19)  ·  Germany (15)  ·  Italy (13)  ·  Australia (10)  ·  Canada (10)  ·  Israel (10)  ·  Spain (10)  ·  Brazil (9)  ·  Poland (6)  ·  Belgium (5)  ·  Denmark (5)  ·  Czechia (4)  ·  Japan (4)

Top investigators

Paul Orchard, MD (3)  ·  Forbes D Porter, M.D. (2)  ·  An N. Dang Do, MD, PhD (1)  ·  Ari Zimran (1)  ·  Caroline Sevin, MD-PhD (1)  ·  Claudia Chiriboga, Assoc. Prof. MD (1)  ·  David Jacoby (1)  ·  Erika F Augustine, MD (1)

Results publications

PMID 27657681, PMID 21586746, PMID 23176611, PMID 23348766, PMID 29688815, PMID 33482890, PMID 33980287, PMID 34349180, PMID 36481125, PMID 38101904, PMID 38776275, PMID 40267426, PMID 18346516, PMID 19595619, PMID 20299511, PMID 20439622, PMID 20713962, PMID 23339116, PMID 23474038, PMID 23860343, PMID 24014509, PMID 24816856, PMID 24835462, PMID 25425121, PMID 25758611, PMID 26252393, PMID 27289174, PMID 27307708, PMID 27866808, PMID 29305734, PMID 30834538, PMID 31184505, PMID 32620536, PMID 32657505, PMID 32792226, PMID 33332761, PMID 33875845, PMID 34387740, PMID 34389161, PMID 34418116, PMID 35065785, PMID 35442238, PMID 36456200, PMID 36739645, PMID 37098529, PMID 37171121, PMID 37670901, PMID 38042851, PMID 39774103, PMID 40525490

NIH funding

2015 (2), 2005 (1), 2014 (1), 2017 (1), 2018 (1), U01HD090845 (1), U54NS065768 (1)